Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Novel Evidence about Hydrogen Sulfide (H2S)-Donor Molecules as...
share announcement

Novel Evidence about Hydrogen Sulfide (H2S)-Donor Molecules as Innovative Therapeutical Tools (Volume II)

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (22 December 2023) | Viewed by 2863

Special Issue Editors

Dr. Alma Martelli

E-Mail Website
Guest Editor
Department of Pharmacy, Università di Pisa, Pisa, Italy
Interests: cardiovascular pharmacology; hydrogen sulfide; nitric oxide; endothelial dysfunction; vascular inflammation; hypertension; natural products; nutraceuticals; isothiocyanates
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Vincenzo Calderone

E-Mail Website
Guest Editor
Department of Pharmacy, University of Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy
Interests: H2S; gasotransmitters; cardiovascular pharmacology; ion channels; metabolic pharmacology; synthetic and natural H2S donors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years the role of hydrogen sulfide (H2S) as endogenous pleiotropic gasotransmitter involved in the maintenance of homeostasis has been demonstrated and as a further confirmation, a decrease of H2S endogenous levels has been recorded in many pathological conditions. On these bases, the research and characterization of H2S-donor molecules, able to release H2S in a slow and gradual way, similar to the physiological production, represents the goal of many excellent research groups around the world. The aim of this special issue is to collect novel evidence about these H2S-releasing drugs in order to consider them as innovative therapeutical tools for unmet medical needs.

Dr. Alma Martelli
Prof. Dr. Vincenzo Calderone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hydrogen sulfide (H2S)-donor
  • H2S-releasing molecule
  • H2S-hybrid drug
  • hydrogen sulfide
  • therapeutical tool

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 2576 KiB  
Article
Contractions Induced in Human Pulmonary Arteries by a H2S Donor, GYY 4137, Are Inhibited by Low-Frequency (20 kHz) Ultrasound
by Agilė Tunaitytė, Silvijus Abramavičius, Augusta Volkevičiūtė, Mantas Venslauskas, Algimantas Bubulis, Vytis Bajoriūnas, Ulf Simonsen, Vytautas Ostaševičius, Vytautas Jūrėnas, Kasparas Briedis and Edgaras Stankevičius
Biomolecules 2024, 14(3), 257; https://0-doi-org.brum.beds.ac.uk/10.3390/biom14030257 - 21 Feb 2024
Viewed by 717
Abstract
The present study aimed to investigate the effect of a H2S donor, GYY 4137, on human pulmonary arteries and whether low-frequency ultrasound (20 kHz, 4 W/cm2) inhibits GYY 4137 contractions. Functional studies were conducted on human and rat pulmonary [...] Read more.
The present study aimed to investigate the effect of a H2S donor, GYY 4137, on human pulmonary arteries and whether low-frequency ultrasound (20 kHz, 4 W/cm2) inhibits GYY 4137 contractions. Functional studies were conducted on human and rat pulmonary arteries mounted on microvascular myographs. We placed an ultrasonic gadget in the tissue organ bath to insonate the arteries with low-frequency ultrasound. To measure the effect of the low-frequency ultrasound on the entrance of extracellular Ca2+, the preparations were placed in a Ca2+-free solution, and the thromboxane agonist, U46619, and extracellular calcium were added in the presence of insonation. In isolated human pulmonary arteries, GYY 4137 induced contractions, which were most pronounced in the arteries contracted with the thromboxane analogue, U46619. The transient GYY4137 contractions were reversed by low-frequency ultrasound, a blocker of KV7 channels, XE-991 (10 µM), and glibenclamide (1 μM), a blocker of ATP-sensitive channels. Low-frequency ultrasound also inhibited the contractions induced by the smooth muscle entrance of increasing extracellular calcium concentrations. The present findings show that GYY 4137 can cause a transient contraction of pulmonary arteries in human arteries. GYY 4137 alone does not cause significant vascular contraction in rat lung arteries, but it contracts rat lung arteries precontracted with U46619. The transient contractions induced by GYY 4137 can be inhibited by low-frequency ultrasound, probably by counteracting the influx of external Ca2+. The effect of low-frequency ultrasound counteracts contraction in pulmonary arteries; therefore, a possibility could be to develop a larger device allowing treatment of patients with pulmonary hypertension. Full article
(This article belongs to the Special Issue Novel Evidence about Hydrogen Sulfide (H2S)-Donor Molecules as Innovative Therapeutical Tools (Volume II))
►▼ Show Figures

Figure 1

Other

Jump to: Research

16 pages, 1725 KiB  
Systematic Review
Circulating Levels of Hydrogen Sulfide (H2S) in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis
by Eugenia Piragine, Marco Andrea Malanima, Ersilia Lucenteforte, Alma Martelli and Vincenzo Calderone
Biomolecules 2023, 13(7), 1023; https://0-doi-org.brum.beds.ac.uk/10.3390/biom13071023 - 21 Jun 2023
Cited by 7 | Viewed by 1793
Abstract
Hydrogen sulfide (H2S) is an endogenous gasotransmitter that promotes multiple biological effects in many organs and tissues. An imbalanced biosynthesis of H2S has been observed in animal models of age-related pathological conditions. However, the results from human studies are [...] Read more.
Hydrogen sulfide (H2S) is an endogenous gasotransmitter that promotes multiple biological effects in many organs and tissues. An imbalanced biosynthesis of H2S has been observed in animal models of age-related pathological conditions. However, the results from human studies are inconsistent. We performed a systematic review with meta-analysis of studies searched in Medline, Embase, Scopus, and CENTRAL databases. We included observational studies on patients with age-related diseases showing levels of H2S in blood, plasma, or serum. All the analyses were carried out with R software. 31 studies were included in the systematic review and 21 in the meta-analysis. The circulating levels of H2S were significantly reduced in patients with progressive, chronic, and degenerative diseases compared with healthy people (standardized mean difference, SMD: −1.25; 95% confidence interval, CI: −1.98; −0.52). When we stratified results by type of disorder, we observed a significant reduction in circulating levels of H2S in patients with vascular disease (e.g., hypertension) (SMD: −1.32; 95% CI: −2.43; −0.22) or kidney disease (SMD: −2.24; 95% CI: −4.40; −0.08) compared with the control group. These results could support the potential use of compounds targeting the “H2S system” to slow down the progression of many diseases in the elderly. Full article
(This article belongs to the Special Issue Novel Evidence about Hydrogen Sulfide (H2S)-Donor Molecules as Innovative Therapeutical Tools (Volume II))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop